Skip to main content
SpringerLink
Log in

The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

BackgroundCYP2C19 loss-of-function polymorphic alleles (*2 and *3) have been documented to impair clopidogrel metabolism, and represent a risk factor for major adverse cardiac events. CYP2C19 polymorphism exhibits marked ethnic heterogeneity. Objective To determine the prevalence of CYP2C19 *2 and *3 alleles in a cohort of Palestinian patients managed with percutaneous coronary intervention and dual antiplatelet therapy, and to determine their role in causing major adverse cardiac events. Setting The blood samples were collected at the European Gaza Hospital, and the molecular techniques performed at the molecular genetics laboratory of the Islamic university of Gaza. Method The frequency of CYP2C19 *2 and *3 alleles was determined in 110 patients managed with percutaneous coronary intervention and clopidogrel. Genotyping was performed by PCR–RFLP. Personal and clinical data was obtained from patient record and 6-month follow-up for major adverse cardiac events. Main outcome measureCYP2C19 genotype, personal and clinical data and incidence of major adverse cardiac events. Results The frequency of CYP2C19 *1, *2 and *3 alleles was 82.3%, 15.5% and 2.3% respectively. Genotyping analysis showed that, 67.3% were homozygotes for CYP2C19 *1, 27.3% were *1/*2, 2.7% with *1/*3 genotype, 1.8% were *2/*3 and 0.9% were *2/*2. These frequencies were consistent with those of Caucasian populations. According to this study the poor metabolizers phenotype frequency was 2.7%, which is in the same range reported in Caucasians (2–5%) and lower than Oriental populations 13–23%. A strong significant relation was found between major adverse cardiac events and carrying the variant allele CYP2C19 *2 (P = 0.001). On the other hand, there was no significant relation between major adverse cardiac events and carrying the variant allele CYP2C19 *3 (P = 0.324). Conclusion The CYP2C19 *2 allele is relatively common in our population, and its associated reduced metabolic activity deserves attention as it leads to an increased incidence of major adverse cardiac events in the follow-up of patients receiving clopidogrel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO. Cardiovascular diseases (CVDs). In: Fact sheets. WHO. 2017. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 19 Oct 2018.

  2. Bowry AD, Lewey J, Dugani SB, Choudhry NK. The burden of cardiovascular disease in low- and middle-income countries: epidemiology and management. Can J Cardiol. 2015;31(9):1151–9.

    Article  Google Scholar 

  3. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.

    Article  Google Scholar 

  4. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.

    Article  Google Scholar 

  5. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133(11):1135–47.

    Article  Google Scholar 

  6. Ge J, Yu H, Li J. Acute coronary stent thrombosis in modern era: etiology, treatment, and prognosis. Cardiology. 2017;137(4):246–55.

    Article  Google Scholar 

  7. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134(10):e123–55.

    Article  Google Scholar 

  8. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–20.

    Article  CAS  Google Scholar 

  9. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl 2:15–9.

    CAS  PubMed  Google Scholar 

  10. Nurden PSPNA, Herbert SL-TJ-M. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9(3–4):251–5.

    Google Scholar 

  11. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44(3):527–32.

    Article  CAS  Google Scholar 

  12. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891–6.

    Article  CAS  Google Scholar 

  13. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92–9.

    Article  CAS  Google Scholar 

  14. Ray S. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66(5):530–4.

    Article  CAS  Google Scholar 

  15. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res. 2007;120(3):311–21.

    Article  CAS  Google Scholar 

  16. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–62.

    Article  CAS  Google Scholar 

  17. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19* 2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011;11(3):199–206.

    Article  CAS  Google Scholar 

  18. Subraja K, Dkhar S, Priyadharsini R, Ravindra B, Shewade D, Satheesh S, et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol. 2013;69(3):415–22.

    Article  CAS  Google Scholar 

  19. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30.

    Article  CAS  Google Scholar 

  20. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704–14.

    Article  CAS  Google Scholar 

  21. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis. 2011;32(4):459.

    Article  CAS  Google Scholar 

  22. Collet J-P, Hulot J-S, Pena A, Villard E, Esteve J-B, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. The Lancet. 2009;373(9660):309–17.

    Article  CAS  Google Scholar 

  23. Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenetics Genomics. 2012;22(12):887–90.

    Article  CAS  Google Scholar 

  24. Jeong YH, Abadilla KA, Tantry US, Park Y, Koh JS, Kwak CH, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost. 2013;11(6):1194–7.

    Article  CAS  Google Scholar 

  25. Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, et al. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Int J Clin Pharm. 2013;35(4):621–8.

    Article  CAS  Google Scholar 

  26. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19* 5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics Genomics. 1998;8(2):129–36.

    Article  CAS  Google Scholar 

  27. Dean L. Clopidogrel Therapy and CYP2C19 Genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda, MD: National Center for Biotechnology Information; 2012.

    Google Scholar 

  28. Palestinian Health Information Center. Deaths in Gaza strip. In: Madi K, editor. 2016 Annual Report. Gaza, Palestine: Ministry of health; 2017.

  29. Palestinian Health Information Center. Hospitals in Gaza Strip. In: Nassar B, editor. 2016 Annual Report. Gaza, Palestine: Ministry of health; 2017.

  30. Goldstein JA, Blaisdell J. [23] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996;272:210–8.

    Article  CAS  Google Scholar 

  31. Nakamoto K, Kidd JR, Jenison RD, Klaassen CD, Wan Y-JY, Kidd KK, et al. Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenetics Genomics. 2007;17(2):103–14.

    Article  CAS  Google Scholar 

  32. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genetics. 2010;55(9):582–9.

    Article  CAS  Google Scholar 

  33. Ensembl-a. Ensembl release 89. EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom. 2017. http://May2017.archive.ensembl.org/Homo_sapiens/Variation/Population?db=core;g=ENSG00000165841;r=10:94762624-94853260;v=rs4244285;vdb=variation;vf=2675574. Accessed 19 Oct 2018.

  34. Buzoianu AD, Trifa AP, Popp RA, Militaru MS, Militaru CF, Bocşan CI, et al. Screening for CYP2C19* 2,* 3 and* 4 gene variants in a Romanian population study group. Farmacia. 2010;56:806–17.

    Google Scholar 

  35. Khalil BM, Shahin MH, Solayman MHM, Langaee T, Schaalan MF, Gong Y, et al. Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population. Clin Transl Sci. 2016;9(1):23–8.

    Article  CAS  Google Scholar 

  36. Saeed LH, Mayet AY. Genotype-phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci. 2013;10(11):1497–502.

    Article  Google Scholar 

  37. Jureidini ID, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep. 2011;38(8):5449–52.

    Article  Google Scholar 

  38. Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19* 1 and CYP2C19* 2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep. 2012;39(4):4195–200.

    Article  CAS  Google Scholar 

  39. Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther. 1999;65(3):275–82.

    Article  CAS  Google Scholar 

  40. Abid L, Laroussi L, Bahloul A, Siala A, Abdelhédi R, Kharrat N et al. Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region. World J Cardiovasc Dis. 2013;3(1):4–10.

    Article  Google Scholar 

  41. Sameer A, Amany GM, Abdela AA, Fadel SA. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol. 2009;16(1):e156–62.

    PubMed  Google Scholar 

  42. Nassar S, Amro O, Abu-Rmaileh H, Alshaer I, Korachi M, Ayesh S. ABCB1 C3435T and CYP2C19* 2 polymorphisms in a Palestinian and Turkish population: a pharmacogenetic perspective to clopidogrel. Meta gene. 2014;2:314–9.

    Article  Google Scholar 

  43. Ensembl-b. Ensembl release 89. EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom. 2017. http://May2017.archive.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=10:94780153-94781153;v=rs4986893;vdb=variation;vf=3218155. Accessed 19 Oct 2018.

  44. De Morais S, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594–8.

    PubMed  Google Scholar 

  45. Al-Jenoobi FI, Alkharfy KM, Alghamdi AM, Bagulb KM, Al-Mohizea AM, Al-Muhsen S, et al. CYP2C19 genetic polymorphism in Saudi Arabians. Basic Clin Pharmacol Toxicol. 2013;112(1):50–4.

    Article  CAS  Google Scholar 

  46. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007;34(1–2):102–5.

    Article  CAS  Google Scholar 

  47. Shahabi-Majd N, Habashi B. Frequencies of two CYP2C19 defective alleles (CYP2C19* 2, and* 3) among Iranian population in Mazandaran Province. Res Mol Med. 2013;1(1):17–21.

    CAS  Google Scholar 

  48. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics Genomics. 1997;7(1):59–64.

    Article  CAS  Google Scholar 

  49. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999;66(2):185–92.

    Article  CAS  Google Scholar 

  50. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916–22.

    Article  CAS  Google Scholar 

  51. Wei YQ, Wang DG, Yang H, Cao H. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome. PLoS ONE. 2015;10(7):e0132561.

    Article  Google Scholar 

  52. Guo B, Tan Q, Guo D, Shi Z, Zhang C, Guo W. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014;60(4):993–1001.

    Article  Google Scholar 

  53. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (Clinical research ed). 2011;343:d4588.

    Article  Google Scholar 

  54. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–105.

    Article  CAS  Google Scholar 

  55. Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2015;135(3):449–58.

    Article  CAS  Google Scholar 

  56. Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE. 2013;8(10):e78549.

    Article  CAS  Google Scholar 

  57. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet. 2010;376(9748):1233–43.

    Article  CAS  Google Scholar 

  58. Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv. 2011;4(4):392–402.

    Article  Google Scholar 

  59. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation. 2004;109(4):476–80.

    Article  Google Scholar 

  60. Bach R, Jung F, Kohsiek I, Özbek C, Spitzer S, Scheller B, et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thromb Res. 1994;74:S55–67.

    Article  Google Scholar 

  61. Qin S-Y, Zhou Y, Jiang H-X, Hu B-L, Tao L, M-z Xie. The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS ONE. 2013;8(9):e72710.

    Article  CAS  Google Scholar 

  62. Mohan S, Dhall A. A comparative study of restenosis rates in bare metal and drug-eluting stents. Int J Angiol. 2010;19(02):e66–72.

    Article  Google Scholar 

  63. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Shimshak TM, et al. Comparison of procedural results and risks of coronary angioplasty in men and women for conditions other than acute myocardial infarction. Am J Cardiol. 1992;69(14):1241–2.

    Article  CAS  Google Scholar 

  64. Bell MR, Holmes DR, Berger PB, Garratt KN, Bailey KR, Gersh BJ. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA. 1993;269(16):2091–5.

    Article  CAS  Google Scholar 

  65. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol. 2001;88(8):848–52.

    Article  CAS  Google Scholar 

  66. Jacobs AK, Johnston JM, Haviland A, Brooks MM, Kelsey SF, Holmes DR, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol. 2002;39(10):1608–14.

    Article  Google Scholar 

  67. Macdonald RG, Henderson MA, Hirshfeld JW, Goldberg SH, Bass T, Vetrovec G, et al. Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty—a report from the M-HEART Groupt. Am J Cardiol. 1990;66(12):926–31.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the cardiac catheterization department of the European Gaza Hospital for facilitating the recruitment of patients.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Laboratory Medical Sciences, Faculty of Medical Sciences, Alaqsa University, Gaza, Palestine

    Basim M. Ayesh

  2. Naser Medical Complex, Laboratory Department, Ministry of Health, Gaza, Palestine

    Ibrahim R. Al-Astal

  3. Faculty of Medicine, the Islamic University of Gaza, Gaza, Palestine

    Maged M. Yassin

Authors
  1. Basim M. Ayesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim R. Al-Astal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maged M. Yassin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basim M. Ayesh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayesh, B.M., Al-Astal, I.R. & Yassin, M.M. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. Int J Clin Pharm 41, 96–103 (2019). https://doi.org/10.1007/s11096-018-00782-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-018-00782-3

Keywords

Search

Navigation